← All stocks

Contineum Therapeutics, Inc.

CTNM Scheduled selling only

CIK 0001855175 #2951 in the set updated 17 Sep 2026

Bought (120 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$1.98M

$502.61K on a plan · $1.47M straight out of an exercise

Sold at will

$0.00

0 of 34 sales

Net

−$1.98M

$0.00 against sales at will

By person

5 insiders · 35 transactions

0.4×

Carmine N. Stengone holds only 0.4 times base salary in stock. $283.33K of shares against $655.62K in salary for 2025.

Salary from the company's own proxy. The shares are what Carmine N. Stengone last reported holding, valued at $16.46, the price Class A Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Lorrain Daniel S.

Chief Scientific Officer

—

$1.25M (22) scheduled

−$1.25M

135,202

0.5853%

$2.22M

−23.1%

Stengone Carmine N.

CEO and President

—

$401.38K (7) scheduled

−$401.38K

17,217

0.0745%

$283.33K

0.0%

Watkins Tim

CMO & Head of Development

—

$322.56K (5) scheduled

−$322.56K

8,961

0.0388%

$147.47K

0.0%

Versant Venture Capital VI, L.P. entity

10% owner

—

148,312

0.6421%

$2.44M

—

Huhn Stephen L.

CMO & Sr VP, Clinical Dev.

—

12,800

0.0554%

$210.64K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Huhn Stephen L.

13 Aug 2024

CMO & Sr VP, Clinical Dev.

Exercised, kept

12,800

$1.01

$12.93K

Show all 35 transactions →

What was left out

Form 4 filings counted 63

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 1

Sales on a Rule 10b5-1 plan 13

Sales straight out of an exercise 21

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 644,767

History held since 11 Apr 2024